ATE312081T1 - 6-phenylphenanthridine mit pde-iv hemmender wirkung - Google Patents

6-phenylphenanthridine mit pde-iv hemmender wirkung

Info

Publication number
ATE312081T1
ATE312081T1 AT00901534T AT00901534T ATE312081T1 AT E312081 T1 ATE312081 T1 AT E312081T1 AT 00901534 T AT00901534 T AT 00901534T AT 00901534 T AT00901534 T AT 00901534T AT E312081 T1 ATE312081 T1 AT E312081T1
Authority
AT
Austria
Prior art keywords
phenylphenanthridine
pde
inhibiting effect
compounds
formula
Prior art date
Application number
AT00901534T
Other languages
English (en)
Inventor
Dieter Flockerzi
Herrmann Amschler
Gerhard Grundler
Armin Hatzelmann
Daniela Bundschuh
Rolf Beume
Hildegard Boss
Hans-Peter Kley
Beate Gutterer
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Application granted granted Critical
Publication of ATE312081T1 publication Critical patent/ATE312081T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
AT00901534T 1999-01-15 2000-01-12 6-phenylphenanthridine mit pde-iv hemmender wirkung ATE312081T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99100694 1999-01-15
PCT/EP2000/000172 WO2000042020A1 (en) 1999-01-15 2000-01-12 Phenylphenanthridines with pde-iv inhibiting activity

Publications (1)

Publication Number Publication Date
ATE312081T1 true ATE312081T1 (de) 2005-12-15

Family

ID=8237351

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00901534T ATE312081T1 (de) 1999-01-15 2000-01-12 6-phenylphenanthridine mit pde-iv hemmender wirkung

Country Status (32)

Country Link
US (1) US6476025B1 (de)
EP (2) EP1650193A3 (de)
JP (1) JP4653314B2 (de)
KR (1) KR100720906B1 (de)
CN (1) CN1152864C (de)
AT (1) ATE312081T1 (de)
AU (1) AU774868B2 (de)
BG (1) BG65126B1 (de)
BR (1) BR0007527B1 (de)
CA (1) CA2359440C (de)
CY (1) CY1106436T1 (de)
CZ (1) CZ300366B6 (de)
DE (1) DE60024581T2 (de)
DK (1) DK1147089T3 (de)
EA (1) EA003780B1 (de)
EE (1) EE05105B1 (de)
ES (1) ES2254132T3 (de)
HK (1) HK1040997B (de)
HR (1) HRP20010578A2 (de)
HU (1) HU227624B1 (de)
ID (1) ID29070A (de)
IL (2) IL144026A0 (de)
NO (1) NO320182B1 (de)
NZ (1) NZ512872A (de)
PL (1) PL205670B1 (de)
RS (1) RS50297B (de)
SI (1) SI1147089T1 (de)
SK (1) SK286946B6 (de)
TR (2) TR200501553T2 (de)
UA (1) UA69436C2 (de)
WO (1) WO2000042020A1 (de)
ZA (1) ZA200104864B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001267589A1 (en) * 2000-07-14 2002-01-30 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Cycloalkyl - or cycloalkylmethyl-substituted 6-phenylphenanthridines
PL374014A1 (en) * 2002-08-17 2005-09-19 Altana Pharma Ag Novel phenanthridines having pde 3/4 inhibiting properties
US7423046B2 (en) * 2002-08-29 2008-09-09 Nycomed Gmbh 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
WO2004019944A1 (en) 2002-08-29 2004-03-11 Altana Pharma Ag 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
US6894061B2 (en) 2002-12-04 2005-05-17 Wyeth Substituted dihydrophenanthridinesulfonamides
EP1658270A1 (de) * 2003-07-31 2006-05-24 ALTANA Pharma AG Neue 6-phenylphenantridine
WO2005012253A1 (en) * 2003-07-31 2005-02-10 Altana Pharma Ag Novel 6-phenylphenanthridines
US7776893B2 (en) 2003-09-05 2010-08-17 Nycomed Gmbh Use of PDE4 inhibitors for the treatment of diabetes mellitus
WO2005077906A1 (en) 2004-02-18 2005-08-25 Altana Pharma Ag Novel guanidinyl-substituted hydroxy-6-phenylphenenthridines as effective phosphodiesterase (pde) 4 inhibitors
AU2005219576B2 (en) 2004-03-03 2011-06-30 Takeda Gmbh Novel hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors
AR049419A1 (es) * 2004-03-03 2006-08-02 Altana Pharma Ag Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo
WO2005084104A2 (en) * 2004-03-09 2005-09-15 Altana Pharma Ag Novel isoamido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
JP2007527900A (ja) * 2004-03-10 2007-10-04 アルタナ　ファルマ　アクチエンゲゼルシャフト チオ含有の新規のヒドロキシ−６−フェニルフェナントリジン及びｐｄｅ４インヒビターとしてのそれらの使用
NZ549254A (en) * 2004-03-10 2010-06-25 Nycomed Gmbh Amido-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors
CA2558532A1 (en) * 2004-03-10 2005-09-15 Altana Pharma Ag Novel difluoroethoxy-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
AU2005281703B2 (en) 2004-09-08 2011-11-17 Takeda Gmbh Novel 3-thia-10-aza-phenanthrene derivatives
US7411093B2 (en) 2004-12-20 2008-08-12 Hoffman-La Roche Inc. Aminocycloalkanes as DPP-IV inhibitors
PT1856093E (pt) * 2005-03-02 2010-02-08 Nycomed Gmbh Sal hcl de (2r,4ar,10br)-6-(2,6-dimetoxipiridin-3-il)-9-etoxi- 8-metoxi-1,2,3,4,4a,10b-hexa-hidrofenantridin-2-ol
BRPI0609371A2 (pt) 2005-03-08 2010-03-30 Nycomed Gmbh usos de roflumilast na produção de composições farmacêuticas para o tratamento de diabetes mellitus
AU2006221957A1 (en) * 2005-03-09 2006-09-14 Nycomed Gmbh Amido-substituted 6-phenylphenanthridines
MX2010003155A (es) 2007-10-04 2010-04-01 Hoffmann La Roche Derivados de ciclopropil aril amida y uso de los mismos.
CA2857344C (en) 2011-12-21 2019-02-12 Novira Therapeutics, Inc. Hepatitis b antiviral agents
JP6505013B2 (ja) 2012-08-28 2019-04-24 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用
AU2014222641B2 (en) 2013-02-28 2018-03-15 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of Hepatitis B
JP6419155B2 (ja) 2013-04-03 2018-11-07 ヤンセン・サイエンシズ・アイルランド・ユーシー Ｎ−フェニル−カルボキサミド誘導体およびｂ型肝炎を治療するための医薬品としてのその使用
US10160743B2 (en) 2013-05-17 2018-12-25 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
LT3024819T (lt) 2013-07-25 2018-06-11 Janssen Sciences Ireland Uc Pirolamido dariniai, turintys glioksamido pakaitų, ir jų panaudojimas kaip vaistų hepatito b gydymui
WO2015059212A1 (en) 2013-10-23 2015-04-30 Janssen R&D Ireland Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
MX2016009449A (es) 2014-02-05 2016-10-13 Novira Therapeutics Inc Terapia de combinacion para el tratamiento de infecciones por virus de la hepatitis b (vhb).
EP3102572B1 (de) 2014-02-06 2018-10-24 Janssen Sciences Ireland UC Sulphamoylpyrrolamide und deren verwendung als medikamente zur behandlung von hepatitis b
JP2018510159A (ja) 2015-03-19 2018-04-12 ノヴィラ・セラピューティクス・インコーポレイテッド アゾカン及びアゾナン誘導体及びｂ型肝炎感染症の治療法
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
AU2016330964B2 (en) 2015-09-29 2021-04-01 Novira Therapeutics, Inc. Crystalline forms of a hepatitis B antiviral agent
AU2017248828A1 (en) 2016-04-15 2018-11-01 Janssen Sciences Ireland Uc Combinations and methods comprising a capsid assembly inhibitor
US10973801B2 (en) 2018-03-14 2021-04-13 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
CN113454077A (zh) 2019-02-22 2021-09-28 爱尔兰詹森科学公司 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物
MX2021013594A (es) 2019-05-06 2021-12-10 Janssen Sciences Ireland Unlimited Co Derivados de amida utiles en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3899494A (en) * 1970-05-13 1975-08-12 Sandoz Ltd Substituted 6-phenyl benzo-naphthyridines
SI0882021T1 (en) 1996-01-31 2003-10-31 Altana Pharma Ag New phenanthridines
US6127378A (en) 1996-03-26 2000-10-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridines substituted in the 6 position
WO1997035854A1 (de) * 1996-03-26 1997-10-02 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue in 6-position substituierte phenanthridine
SK283269B6 (sk) * 1996-11-11 2003-04-01 Altana Pharma Ag Benzonaftyridíny, farmaceutický prostriedok s ich obsahom a ich použitie
ATE248167T1 (de) 1997-03-07 2003-09-15 Altana Pharma Ag Tetrazole derivate
AU8106598A (en) 1997-06-03 1998-12-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Benzonaphthyridine
PT998460E (pt) * 1997-07-25 2004-07-30 Altana Pharma Ag Novos derivados de tetrazole
HUP0003311A3 (en) * 1997-07-25 2002-10-28 Altana Pharma Ag Substituted 6-phenylphenanthridine derivatives, pocess for producing them and pharmaceutical compositions containing them
ES2242594T3 (es) * 1999-01-15 2005-11-16 Altana Pharma Ag N-oxidos de fenantridinas con una acitvidad inhidora de pde-iv.
DK1147088T3 (da) * 1999-01-15 2006-05-15 Altana Pharma Ag 6-arylphenanthridiner med PDE-IV-inhiberende aktivitet
EP1147103B1 (de) * 1999-01-15 2005-05-04 ALTANA Pharma AG Phenantrhridin-n-oxides mit pde-iv hemmender wirkung

Also Published As

Publication number Publication date
IL144026A (en) 2007-05-15
NO320182B1 (no) 2005-11-07
HUP0105001A2 (hu) 2002-04-29
AU774868B2 (en) 2004-07-08
EE05105B1 (et) 2008-12-15
ZA200104864B (en) 2003-04-15
CZ300366B6 (cs) 2009-05-06
NO20013341D0 (no) 2001-07-05
NZ512872A (en) 2003-07-25
HRP20010578A2 (en) 2002-08-31
CA2359440A1 (en) 2000-07-20
NO20013341L (no) 2001-09-17
AU2289600A (en) 2000-08-01
BR0007527A (pt) 2001-12-04
DE60024581T2 (de) 2006-08-10
DK1147089T3 (da) 2006-04-10
EP1650193A3 (de) 2006-10-04
PL205670B1 (pl) 2010-05-31
CY1106436T1 (el) 2011-10-12
EA200100731A1 (ru) 2002-02-28
EP1650193A2 (de) 2006-04-26
ID29070A (id) 2001-07-26
SI1147089T1 (sl) 2006-04-30
EA003780B1 (ru) 2003-08-28
KR100720906B1 (ko) 2007-05-25
SK9802001A3 (en) 2001-12-03
EP1147089A1 (de) 2001-10-24
UA69436C2 (uk) 2004-09-15
US6476025B1 (en) 2002-11-05
YU48701A (sh) 2004-05-12
DE60024581D1 (de) 2006-01-12
HK1040997B (zh) 2006-07-14
EE200100350A (et) 2002-10-15
KR20010086164A (ko) 2001-09-08
CZ20012248A3 (cs) 2001-09-12
EP1147089B1 (de) 2005-12-07
PL348925A1 (en) 2002-06-17
SK286946B6 (sk) 2009-08-06
WO2000042020A1 (en) 2000-07-20
ES2254132T3 (es) 2006-06-16
HK1040997A1 (en) 2002-06-28
HUP0105001A3 (en) 2002-10-28
BG105561A (en) 2001-12-29
HU227624B1 (en) 2011-09-28
JP4653314B2 (ja) 2011-03-16
IL144026A0 (en) 2002-04-21
JP2002534508A (ja) 2002-10-15
CN1336919A (zh) 2002-02-20
BR0007527B1 (pt) 2011-12-27
RS50297B (sr) 2009-09-08
CA2359440C (en) 2009-04-14
BG65126B1 (bg) 2007-03-30
CN1152864C (zh) 2004-06-09
TR200101938T2 (tr) 2001-12-21
TR200501553T2 (tr) 2005-06-21

Similar Documents

Publication Publication Date Title
ATE312081T1 (de) 6-phenylphenanthridine mit pde-iv hemmender wirkung
EE200000033A (et) Uudsed tetrasoolderivaadid
ATE294793T1 (de) Phenantrhridin-n-oxides mit pde-iv hemmender wirkung
ATE356810T1 (de) Polysubstituted 6-phenylphenanthridines mit pde- iv hemmender wirkung
ATE315029T1 (de) 6-arylphenanthridine mit pde-iv hemmender wirkung
ATE295352T1 (de) Phenanthridine-n-oxide mit pde-iv hemmender wirkung
DE59909760D1 (de) Benzonaphthyridin-n-oxide mit pde3 und pde4 inhibierender aktivität
ATE258930T1 (de) Dihydrobenzifurane

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1147089

Country of ref document: EP

EEIH Change in the person of patent owner